Cyclopropane is the smallest cyclic compound with unique structural features and physicochemical properties, which is widely used in the design of small molecule drugs. In drug design, it is often used to increase activity, fix conformation and improve PK and water solubility. The introduction of cyclopropyl groups into drugs can change various properties of molecules, such as improving metabolic stability; increasing biological activity; enhancing drug efficacy; limiting polypeptide conformation and slowing down its hydrolysis; reducing plasma clearance; improving drug dissociation and many more. Cyclopropane rings are widely found in marketed drugs, including cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, autoimmune and anti-inflammatory drugs.
Vertex Pharmaceuticals announced that Health Canada has accepted for review its New Drug Submission (NDS) for vanzacaftor/tezacaftor/deutivacaftor, a once-daily triple combination therapy for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor is also undergoing regulatory review in multiple other jurisdictions, including by the Food and Drug Administration (FDA) in the U.S. and by the European Medicines Agency (EMA) in the E.U. Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
検索 
+86 21 5895 0110 
